索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]杨进刚.糖脂代谢异常患者血脂管理新思路[J].国际心血管病杂志,2016,05:315-317.
点击复制

糖脂代谢异常患者血脂管理新思路(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年05期
页码:
315-317
栏目:
讲座
出版日期:
2016-09-20

文章信息/Info

Title:
-
作者:
杨进刚
100037 北京,中国医学科学院阜外心血管病医院
Author(s):
-
关键词:
-
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.05.017
文献标识码:
-
摘要:
-
Abstract:
-

参考文献/References

[1] 敬 华,许樟荣,杨晋德,等.糖尿病2545例血脂检测结果与临床分析[J].中国实验诊断学,2004,8(4):415-417.
[2] Ghandehari H,Kamal-Bahl S,Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels inUS adults with and without cardiovascular comorbidities:the National Health and Nutrition Examination Survey 2003-2004[J].Am Heart J,2008,156(1):112-119.
[3] 郭 莲,刘维娟,徐 伟,等.匹伐他汀对2型糖尿病脂代谢紊乱的调脂作用研究[J].中国药房,2011,22(18):1696-1698.
[4] Moura FA, Saraiva F, Faria ED, et al. Seasonal variation of lipid profile and prevalence of dyslipidemia:A large population study[J]. J Am Coll Cardiol, 2013, 61(10):E1330.
[5] Pinsky JL,Branch LG, Jette AM,et al. Framingham Disability Study: relationship of disability to cardiovascular risk factors among persons free of diagnosed cardiovascular disease[J]. Am J Epidemiol, 1985, 122(4):644-656.
[6] Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials[J].BMJ, 2002, 324(7339):705.
[7] Steiner G,Stewart D,Hosking JD.Baseline Characteristics of the study population in the diabetes AtheroscerosisIntertention Study(DAIS).World Health Organization Collabrating Centre for the study of Atheroscerosis in Diabetes[J]. J Am Cardiol,1999,84(9):1004-1010.
[8] 陈姝君,陈海平, 他汀类药物对糖尿病肾病保护机制的研究进展[J].医学临床研究,2008,25(10):1900-1903.
[9] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013年版)[J]. 中国糖尿病杂志, 2014, 88(8):26-89.
[10] Catapano AL, Chapman J, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology(ESC)and the European Atherosclerosis Society(EAS).[J]. Atherosclerosis, 2011, 217(1):3-46.
[11] Inzucchi S, Bergenstal R, Buse J, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)[J].Diabetes Care, 2012,35(6):1364-1379.
[12] Patti G, TomaiF, Melfi R,et al. Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID(Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting)study[J].J Am Cardiol, 2013, 61(13):1379-1387.
[13] Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2(Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty)[J]. Circulation, 2005, 14(16):44.
[14] Hollaway B, Jensen C, Steinmann H, et al. Tolerability and efficacy of pitava statin among hyperlipidemic patients intolerant to at least two other statins [J]. JACC, 2013, 61(10):E1465.
[15] 武芳莉,董金华. 匹伐他汀钙(pitavastatin)[J].中国药物化学杂志,2010,20(2):155.
[16] Borghi C, Cicero AF. Which statin is the ideal statin for polymedicated patients [J]. Clinical Lipidology, 2012, 7(3s):11-16.
[17] 杨建云,彭水芳,于 锋.防治冠心病新药——匹伐他汀[J].药学与临床研究,2011,19(6):534-537.
[18] Gumprecht J, Gosho M, Budinski D, et al. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined(mixed)dyslipidaemia[J]. Diabetes Obes Metab, 2011, 13(11):1047-1055.
[19] Kastelein JJ, Braamskamp M. Pitavastatin: an overview of the LIVES study[J]. Clin Lipid, 2015, 7(3s):25-31.
[20] Masana L. Pitavastatin in cardiometabolic disease: therapeutic profile[J]. Cardiovasc Diabetol, 2013, 12(Suppl 1):S2.
[21] Kimura K, Shimano H, Yokote K, et al. Effects of Pitavastatin(LIVALO Tablet)on the Estimated Glomerular Filtration Rate(eGFR)in Hypercholesterolemic Patients with Chronic Kidney Disease[J]. J Atheroscler Thromb, 2010, 17(6):601-609.
[22] Kawai Y, Satoishida R, Motoyama A, et al. Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus[J]. Drug Des Devel Ther, 2011, 5(2):283-397.
[23] da Silva PM.Are all statins the same ? Focus on the efficacy and tolerability of pitavastatin[J].Am J Cardiovasc Drugs, 2011, 11(2):93-107.

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2016-09-20